Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead

Li, Shujin; Sun, Zhi‐Jun

doi:10.1016/j.canlet.2022.215937

Cited by 10 publications

(10 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[137] Moreover, oncolytic viruses are engineered to selectively infect and replicate within cancer cells, leading to targeted destruction. [138,150] In addition to their oncolytic activity, these viruses can be engineered to carry therapeutic payloads, enhancing their efficacy as drug delivery vehicles. [138] This dual-functionality allows for the targeted delivery of therapeutic agents directly to tumor sites, minimizing damage to healthy tissues.…”

Section: Optimized Drug Delivery System Of Nanomedicine Targeting Mdscsmentioning

confidence: 99%

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity

Yang,

Sun

2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Cancer immunotherapy, a field within immunology that aims to enhance the host's anti‐cancer immune response, frequently encounters challenges associated with suboptimal response rates. The presence of myeloid‐derived suppressor cells (MDSCs), crucial constituents of the tumor microenvironment (TME), exacerbates this issue by fostering immunosuppression and impeding T cell differentiation and maturation. Consequently, targeting MDSCs has emerged as crucial for immunotherapy aimed at enhancing anti‐tumor responses. The development of nanomedicines specifically designed to target MDSCs aims to improve the effectiveness of immunotherapy by transforming immunosuppressive tumors into ones more responsive to immune intervention. This review provides a detailed overview of MDSCs in the TME and current strategies targeting these cells. We also highlight the benefits of nanoparticle‐assisted drug delivery systems, including design flexibility, efficient drug loading, and protection against enzymatic degradation. It summarizes advances in nanomedicine targeting MDSCs, covering enhanced treatment efficacy, safety, and modulation of the TME, laying the groundwork for more potent cancer immunotherapy.This article is protected by copyright. All rights reserved

show abstract

Section: Optimized Drug Delivery System Of Nanomedicine Targeting Mdscsmentioning

confidence: 99%

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity

Yang,

Sun

2024

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…In addition, the immune system has special memory cells that can continue to function long after vaccination, preventing the recurrence of tumors. Currently, FDA has approved two treatment vaccines, Sipuleucel-T (Provenge) for advanced prostate cancer that has not responded to endocrine therapy [ 64 ], Talimogene laherparepvec (T-VEC) for advanced melanoma and Bacillus in which T-VEC is based on herpes simplex virus type 1, also known as oncolytic virus therapy [ 65 , 66 ].…”

Section: Cancer Immunotherapymentioning

confidence: 99%

Nanomaterials augmented bioeffects of ultrasound in cancer immunotherapy

Xie,

Zhang,

Wang

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

“…Combination therapy with PD‐1/programmed death‐ligand 1 (PD‐L1) and cytotoxic T‐lymphocyte‐associated antigen‐4 has made great progress and generated excitement in recent years. [ 201 ]…”

Section: Marketing Products and Clinical Trials Of Ovsmentioning

confidence: 99%

“…Combination therapy with PD-1/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 has made great progress and generated excitement in recent years. [201] Although OVT with ICI is an attractive approach, this combination may also have antagonistic effects that should be considered. One problem is that the initiation of a systemic antiviral response may prevent effective OV replication and infection of tumor cells.…”

Section: Ovt Combined With Ici Therapiesmentioning

confidence: 99%

Oncolytic Virus‐Driven Biotherapies from Bench to Bedside

Duan

Wang

Qiao

et al. 2023

Small

View full text Add to dashboard Cite

With advances in cancer biology and an ever‐deepening understanding of molecular virology, oncolytic virus (OV)‐driven therapies have developed rapidly and become a promising alternative to traditional cancer therapies. In recent years, satisfactory results for oncolytic virus therapy (OVT) are achieved at both the cellular and organismal levels, and efforts are being increasingly directed toward clinical trials. Unfortunately, OVT remains ineffective in these trials, especially when performed using only a single OV reagent. In contrast, integrated approaches, such as using immunotherapy, chemotherapy, or radiotherapy, alongside OVT have demonstrated considerable efficacy. The challenges of OVT in clinical efficacy include the restricted scope of intratumoral injections and poor targeting of intravenous administration. Further optimization of OVT delivery is needed before OVs become a viable therapy for tumor treatment. In this review, the development process and antitumor mechanisms of OVs are introduced. The advances in OVT delivery routes to provide perspectives and directions for the improvement of OVT delivery are highlighted. This review also discusses the advantages and limitations of OVT monotherapy and combination therapy through the lens of recent clinical trials and aims to chart a course toward safer and more effective OVT strategies.

show abstract

Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead

Cited by 10 publications

References 146 publications

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity

Nanomaterials augmented bioeffects of ultrasound in cancer immunotherapy

Oncolytic Virus‐Driven Biotherapies from Bench to Bedside

Contact Info

Product

Resources

About